Rishabh Jain, Medical Oncologist at AIIMS, shared a post on LinkedIn:
“ELCC 2026: 7 Thoracic Oncology Trials That Could Shift NSCLC Practice.
Thoracic oncology is clearly moving toward ADCs, resistance biology, and smarter IO strategies. Here are the trials that matter.
- Beamion LUNG-1 (Zongertinib).
A serious T-DXd challenger in HER2-mutant NSCLC.
– Strong focus on CNS activity + durability signals. - BL-B01D1-204-01 (Bispecific ADC).
EGFR/HER axis targeting beyond TKIs.
– Key strategy for post-TKI resistance. - 3082-CL-0101 (ADC platform).
Next-gen ADC sequencing question.
– Watch ILD signals + positioning in treatment flow. - KEYNOTE-671 (Perioperative Pembrolizumab).
Already practice-influencing.
– OS maturity could firmly establish periop IO standard. - TOP (Next-gen IO strategy).
Beyond chemo-IO plateau.
– Selection vs intensification dilemma. - ASTEROID and BECOME.
Resistance-focused trials.
– PD-L1 low + primary/secondary resistance solutions.
Takeaway: We are entering the post-chemo-IO era
– ADCs + precision IO will define next-line standards
Save this for ELCC 2026 updates. Full insights + visuals coming soon.”
Other articles about ELCC on OncoDaily.